Loading
Petros Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Jan 2022.
Petros Pharmaceuticals, Inc.: what insiders have been doing
Petros Pharmaceuticals, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 4 insiders published 6 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Over the last twelve months, not one insider purchase of Petros Pharmaceuticals, Inc. stock was filed.
Compared with its exchange (5,816 companies, median 19 filings), a count of 6 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 3 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
23
Thresholds
n/a
Buy Volume
n/a
3 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -90.2%Entry US$737.50 · Close at T+365 US$72.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$4.6M
Net income-US$43.7M0.0% margin
Valuation
PER (trailing)0.0x
P/Book0.2x
Beta1.96
Balance sheet & cash
Market capUS$127.1k
Total debtUS$7.4M
Free Cash Flow-US$6.7M
Profitability & ownership
ROE-124.4%
ROA-38.8%
% insiders25.6%
% institutions10.2%
Last declaration on 5 June 2026
Declarations23 total
1,875,000 shares0Common StockSEC:0001104659-26-071039:0
375,000 shares0Common StockSEC:0001104659-26-071048:0
500,000 shares0Common StockSEC:0001104659-26-001417:0
4,375,000 shares0Common StockSEC:0001104659-26-000238:0
500,000 shares0Common StockSEC:0001104659-26-000237:0
1,875,000 shares0Common StockSEC:0001104659-26-000233:0
300,000 shares0Common StockSEC:0001104659-25-016197:0
450,000 shares0Common StockSEC:0001104659-25-016200:0
150,000 shares0Common StockSEC:0001104659-25-016203:0
150,000 shares0Common StockSEC:0001104659-25-016202:0
1,000,000 shares0Common StockSEC:0001104659-25-016201:0
49,645 shares0Common StockSEC:0001104659-23-129254:0
6,050 sharesCommon StockSEC:0001104659-23-053226:0
6,050 sharesCommon StockSEC:0001104659-23-053225:0
6,050 sharesCommon StockSEC:0001104659-23-053227:0
6,722 sharesCommon StockSEC:0001104659-23-053224:0
2,515 sharesCommon StockSEC:0001104659-23-006546:0
2,264 sharesCommon StockSEC:0001104659-23-006542:0
2,264 sharesCommon StockSEC:0001104659-23-006545:0
2,264 sharesCommon StockSEC:0001104659-23-006547:0
145,773 shares@ €3.038710.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-22-000036:0
Canonical exit: 22 Mar 2022 (T+90)
500,000 shares@ €2.656531.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-21-144901:0
Canonical exit: 27 Feb 2022 (T+90)
1,661,807 shares@ €1.476758.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001567619-21-018515:0
Canonical exit: 16 Jan 2022 (T+90)
23 of 23 declarations
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. (ticker PTPI) is a United States-based pharmaceutical company that was historically listed on Nasdaq and, after its Nasdaq trading suspension in 2025, continued trading on the OTC Markets under the PTPI symbol. For investors, that market migration is an important signal: the company remains public, but it has a much smaller market profile and a more speculative risk/reward setup than a normal NYSE/Nasdaq issuer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai))
Petros’ core strategy centers on expanding access to selected prescription medicines through the over-the-counter, or OTC, channel. The company says it aims to become a leading innovator in the self-care space by helping transform Rx products into OTC treatment options. In recent SEC filings, Petros also described a proprietary integrated technology platform under development, combining a SaaS layer designed to help pharmaceutical companies operationalize and commercialize an Rx-to-OTC switch with a potential Software as a Medical Device (SaMD) component to support consumer self-selection and compliance with FDA requirements. That makes Petros more than a conventional branded-drug story; it is trying to position itself at the intersection of pharma, digital health, and regulatory workflow software. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm?utm_source=openai))
Read moreShow less
The company’s operating history is tied to the December 2020 merger of Metuchen Pharmaceuticals, LLC with Neurotrope, Inc., which marked a strategic reorientation of the business. Its corporate footprint is in Cranford, New Jersey, United States, and its leadership roster reflects a mix of pharmaceutical, financial, and commercial experience. From an investor-relations standpoint, Petros presents itself as a healthcare platform company focused on a future in which access to medication becomes more efficient and consumer-driven. ([petrospharma.com](https://petrospharma.com/?utm_source=openai))
On the product side, SEC filings indicate that Petros licensed an FDA-approved PDE-5 inhibitor prescription medication for erectile dysfunction from Vivus, Inc. That product exposure gives the company a foothold in a recognizable therapeutic area, but Petros’ broader ambition is to create value through the Rx-to-OTC transition process rather than by scaling a large diversified pharmaceutical portfolio. In practical terms, this means the company’s competitive edge depends on regulatory execution, product positioning, and whether its commercialization platform can attract outside adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai))
Petros operates in a highly competitive and regulated segment, where small companies often face funding constraints, long development timelines, and binary regulatory milestones. Its recent filings point to continued operating losses, cost discipline, and a need to preserve capital, while 2025 financing activity helped support liquidity. The company also disclosed that, after the Nasdaq delisting, its shares continued trading publicly on the OTC market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai))
From a market-position perspective, Petros should be viewed as a niche U.S. healthcare microcap with an ambitious but still unproven model. For French-speaking investors in Europe, the key takeaways are clear: the story is about OTC innovation, FDA-regulated execution, and a potentially scalable software-enabled commercialization model, but it comes with elevated balance-sheet, listing, and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
